Leukaemia

Stem cells have been used to treat diseases of the blood for many years. Listed below are some trials investigating the use of stem cells from cord blood, bone marrow and placental tissue to assist patient recovery. Click on the link provided to find out more about each trial. It remains too early to know which approach will be most suitable. We need evidence collected in clinical trials to determine if a proposed stem cell treatment is both safe and effective.

tagged as Leukaemia

  • Human Placental-Derived Stem Cell Transplantation Location: US
    Overview: This trial aims to compare the safety of transplanting combinations of stem cells from placental with cord blood for a number of different malignant and benign haematological disorders. The trial is being conducted by the New York Medical College and will investigate whether giving placental stem cells at the same time as umbilical cord blood effects the survival of the transplanted stem. The trial expects to enrol 30 patients between March 2013 and December 2019 with any one of 16 diseases including several kinds of Leukaemia, Aplastic Anaemia as well as several benign but severely debilitating, incurable enzyme-linked metabolic disorders such as Gaucher's & Nieman-Pick disease. Patients will be monitored for complications and therapeutic benefit for nine months after the injection.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Placental Stem Cells
  • Pilot Study of Partially Human Leucocyte Antigen-Mismatched Stem Cell Infusions after Chemotherapy for Acute Myeloid Leukaemia Location: Australia
    Overview: This trial aims to evaluate stem cell transfusions from partially mismatched donors for patients with acute myeloid leukaemia (AML).The clinical trial is being conducted at St Vincent's Hospital in Sydney and proposes to enrol 12 patients with AML between November 2012 and January 2015. Participants will receive a nine-day induction chemotherapy treatment for AML. Concurrently the donor receives five days of G-CSF injections, starting on day four. On day 9, the stem cells will be harvested from the donor's peripheral blood via apheresis. The stem cells are divided into four aliquots, the first of which is injected into the patient on the same day. A bone marrow biopsy will be performed between four to five weeks after the stem cell infusion and if remission is confirmed, the patient will be commenced consolidation chemotherapy. If remission is not confirmed, the patient will receive another nine days of induction chemotherapy followed by an aliquot of stem cells and have a further bone marrow biopsy after four weeks. If the patient is seen to be in remission two further cycles of consolidation chemotherapy are given each followed by an aliquot of stem cells. Participants will be monitored for complications and assessed for changes in their clinical condition, including monitoring for evidence of graft versus host disease.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • A Pilot Study of the Role of CD133+ as a Cell Marker for Human Haematopoietic Stem Cells Location: Australia
    Overview: This is an observational study being conducted to determine if a specific category of cells (CD 133+) in a standard blood stem cell transplant affects the degree of successful engraftment. The study is being undertaken by the Pathology Department of the Launceston General Hospital in conjunction with the University of Tasmania. This ongoing study commenced recruitment in March 2009 and expects to enrol 40 participants.
    Link to Clinical Registry
    Trial Design: Observational Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • A phase 1 Multicentre Open Label Dose-Escalation Study of Unrelated, Major Histocompatibility-unmatched Mesenchymal Stem Cells for the Treatment of Steroid Refractory Acute Graft Versus Host Disease in Recipients of Allogeneic Heamatopoietic Stem Cell Transplants Location: Australia
    Overview: This trial aims to evaluate the effect of the transplantation of unmatched bone marrow derived mesenchymal stem cells in the treatment of acute graft versus host disease occurring as a result of a previous donated haematopoietic stem cell transplant. The study is being conducted at the Mater Medical Research Institute and Mater Health in Brisbane and is expected to enrol nine subjects. All participants will receive donated, unmatched, bone marrow derived mesenchymal stem cells and one of three different, escalating doses. Participants will be monitored for complications and assessed for changes in their clinical condition.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Evaluation of Engraftment Kinetics Following Double Unit Umbilical Cord Blood Transplantation in Patients with Life Threatening Haematological Malignancy Location: Australia
    Overview: This trial is designed to investigate the use of a double unit umbilical cord blood infusion in patients with life threatening haematological malignancy but no suitable donor available. The study is being jointly conducted by the Australasian Leukaemia and Lymphoma Group and Amgen Australia. The trial aims to assess whether two units of donated cord blood would improve the engraftment rates as this remains low when only one unit is used. All participants will be monitored for complications and assessed for changes in their clinical condition. According to the information posted on the ANZCTR registry, the trial has not yet commenced.
    Link to Clinical Registry
    Trial Design: Observational Study
    Status: Open - Recruiting
    Stem Cell: Umbilical Cord Stem Cells
  • Phase II Study of Myeloablative Allogeneic Transplantation Using G-CSF Mobilised Peripheral Blood Stem Cells Location: Australia
    Overview: This trial is designed to evaluate the use of stem cells from a matched sibling in reducing the incidence of graft versus host disease (GVHD) in the treatment of haematological malignancy.The trial is being conducted by the Royal Brisbane and Women's Hospital in conjunction with the Queensland Institute of Medical Research. The trial started in June 2004 and proposes to enrol 47 patients with a haematological malignancy that requires chemotherapy and bone marrow transplant. Participants require a sibling with an identical HLA match as a donor for this trial. Donors will receive an injection of pegylated GCSF to release bone marrow stem cells into the circulation. The stem cells will be isolated from the donor's blood and provided to the trial participant once they have received their chemotherapy The patient will then be monitored for complications including for acute GVHD.
    Link to Clinical Registry
    Trial Design: Observational Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells
  • Haploidentical Donor Stem Cell Transplantation for Haematological Malignancies Location: Australia
    Overview: This trial aims to investigate the use of blood stem cells from related donors for the treatment of haematological malignancies such as leukaemia and lymphoma. The trial is being conducted at St Vincent's Hospital in Sydney plans to recruit five patients between May 2009 and February 2014. Participants will receive stem cells from a related donor (haploidentical identical) blood stem cells. Donors will be injected with GCSF following which they will have stem cells harvested from their bone marrow as well as from their peripheral blood (GCSF primed bone marrow harvest + augmentation with peripheral blood stem cells). Patients will initially undergo chemotherapy following which they will be injected with donated stem cells. The patients will also be given the standard GVHD prevention immunosuppression regime. Participants will be monitored for complications and assessed for changes in their clinical condition.
    Link to Clinical Registry
    Trial Design: Observational Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells